Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.11 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.13 | 0.70 | 0.39 | 0.40 | 0.00 | — | 27.78 | — | 24.27 | 106.53 | 57.53 | 138.08 | 32.31 | 27.69 | 19.43 | 32.15 | 52.05 | 72.09 | 54.72 | 57.92 | 77.55 |
| — | — | -98.6% | — | -100.0% | — | -51.7% | — | -24.9% | +284.8% | +196.0% | +329.5% | -37.9% | -61.6% | -64.5% | -44.5% | -32.9% | -3.8% | -29.6% | +6.5% | -27.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | -0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -243.9% | -51.3% | -30.4% | -25.3% | -79.6% | — | -1610.2% | -233.7% | -111.8% | -116.7% | -84.6% | -263.8% | -29.3% | -34.9% | -24.5% | -2.1% | -24.1% | -18.5% | -18.9% | -8.3% | -14.3% |
| — | — | +98.1% | +89.2% | +28.8% | — | -1803.1% | +11.4% | -282.1% | -234.7% | -245.8% | -12224.7% | -21.2% | -88.3% | -29.2% | +74.3% | -68.7% | -66.9% | +4.0% | +75.0% | +70.7% | |
| ROA | -170.6% | -39.0% | -25.1% | -20.1% | -41.3% | -75.6% | -83.0% | -100.3% | -62.2% | -73.8% | -57.7% | -198.2% | -24.6% | -29.6% | -21.2% | -1.9% | -21.8% | -17.0% | -17.7% | -7.7% | -13.2% |
| — | +48.5% | +69.8% | +80.0% | +33.6% | -2.4% | -43.9% | +49.4% | -153.0% | -149.2% | -172.5% | -10313.1% | -12.9% | -73.8% | -19.6% | +75.4% | -64.9% | -62.2% | +5.0% | +73.7% | +67.6% | |
| ROIC | -417.9% | — | -79.8% | -127.8% | — | — | — | — | -848.8% | -525.8% | -536.9% | -1528.7% | -137.3% | -183.6% | -117.5% | -12.4% | -398.1% | -1082.1% | -576.6% | — | — |
| — | — | — | — | — | — | — | — | -518.2% | -186.4% | -356.9% | -12231.0% | +65.5% | +83.0% | +79.6% | — | — | — | +70.9% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | — | 0.01 | 0.03 | 0.04 | — | 18.55 | — | 0.17 | — | 0.05 | 0.10 | 0.08 | 0.04 | 0.04 | 0.05 | 0.05 | 0.02 | 0.03 | 0.03 | 0.04 |
| — | — | -100.0% | — | -76.2% | — | +38298.0% | — | +111.8% | — | +19.4% | +112.1% | +46.4% | +48.7% | +56.5% | +59.5% | +52.1% | +33.0% | +25.6% | -43.6% | -70.9% | |
| Debt / EBITDA | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.64 | 3.01 | 133.42 | 5.64 | 4.42 | 0.71 | 1.04 | 0.87 | 1.93 | 1.17 | 2.69 | 2.15 | 5.57 | 7.10 | 6.57 | 8.95 | 10.50 | 12.30 | 16.39 | 19.17 | 13.91 |
| — | +322.7% | +12767.6% | +544.7% | +128.5% | -39.1% | -61.4% | -59.3% | -65.3% | -83.5% | -59.1% | -76.0% | -46.9% | -42.3% | -59.9% | -53.3% | -24.5% | -24.9% | -61.2% | +43.1% | +45.6% | |
| Quick Ratio | 5.64 | 3.01 | 133.42 | 5.64 | 4.42 | 0.71 | 1.04 | 0.87 | 1.93 | 1.17 | 2.69 | 2.15 | 5.57 | 7.10 | 6.57 | 8.95 | 10.50 | 12.30 | 16.39 | 19.17 | 13.91 |
| — | +322.7% | +12767.6% | +544.7% | +128.5% | -39.1% | -61.4% | -59.3% | -65.3% | -83.5% | -59.1% | -76.0% | -46.9% | -42.3% | -59.9% | -53.3% | -24.5% | -24.9% | -61.2% | +43.1% | +45.6% | |
| Interest Coverage | -11.70 | -6232.75 | -595.69 | -324.17 | -434.66 | -2.97 | -10.13 | -304.33 | -246.00 | -1277.47 | -344.92 | -1041.22 | -141.05 | -3617.73 | -848.97 | -51.07 | -739.27 | -4397.95 | -1413.35 | -448.35 | -620.54 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OGEN stock.
Oragenics, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Oragenics, Inc.'s business trajectory between earnings reports.